高级检索
    刘杨. 阿托伐他汀对扩张型心肌病心功能及C反应蛋白和血浆脑钠肽的影响[J]. 蚌埠医科大学学报, 2011, 36(3): 258-259,262.
    引用本文: 刘杨. 阿托伐他汀对扩张型心肌病心功能及C反应蛋白和血浆脑钠肽的影响[J]. 蚌埠医科大学学报, 2011, 36(3): 258-259,262.
    shu
    LIU Yang. The effect of atrophatatine on cardiac function,C-reactive protein and brain natriuretic peptide in patients with dilated cardiomyopathy[J]. Journal of Bengbu Medical University, 2011, 36(3): 258-259,262.
    Citation: LIU Yang. The effect of atrophatatine on cardiac function,C-reactive protein and brain natriuretic peptide in patients with dilated cardiomyopathy[J]. Journal of Bengbu Medical University, 2011, 36(3): 258-259,262.
    shu

    阿托伐他汀对扩张型心肌病心功能及C反应蛋白和血浆脑钠肽的影响

    The effect of atrophatatine on cardiac function,C-reactive protein and brain natriuretic peptide in patients with dilated cardiomyopathy

      摘要
    • 摘要: 目的: 观察短期应用阿托伐他汀对扩张型心肌病(DCM)心力衰竭患者心功能及C反应蛋白(CRP)、血浆脑钠肽(BNP)的影响。方法: 选择DCM心力衰竭患者40例,随机分为治疗组20例,对照组20例。对照组常规应用纠正心力衰竭药物治疗,治疗组在常规治疗基础上加用阿托伐他汀40 mg,每晚1次,疗程12周。2组入选后次日及治疗12周后测定左心室射血分数(LVEF)、血浆CRP、BNP水平。结果: 2组LVEF较治疗前显著提高(P<0.01),治疗组与对照组差异有统计学意义(P<0.01)。2组CRP和BNP水平均较治疗前显著降低(P<0.01),治疗组与对照组差异均有统计学意义(P<0.01)。结论: 短期应用阿托伐他汀可降低DCM心力衰竭患者CRP水平,改善心功能,有效抑制BNP水平。其改善心功能作用机制可能与他汀类调脂以外的抗炎作用有部分关系,短期应用他汀类治疗DCM心力衰竭可能是有益的。

       

      Abstract: Objective: To observe the effect of atorvastatin on cardiac function,C-reaction protein (CRP) and serum level of brain natriuretic peptide (BNP) in patients of heart failure (HF) with dilated cardiomyopathy (DCM). Methods: Forty patients with DCM and HF were randomly divided into treatment group and control group. The control group was given conventional drug therapy. The treatment group was given atorvastatin (40 mg/d,12 weeks) in addition to routine treatment. The left ventricular ejection fraction (LVEF),CRP and BNP were measured before and after treatment. Results: After 12 weeks,the LVEF was dramatically higher in all patients (P<0.01),and the LVEF in treatment group was significantly higher than that in the conventional therapy group (P<0.01). The serum level of CRP and BNP was dramatically lower in all patients (P<0.01). Also,the serum level of CRP and BNP was significantly lower in the treatment group when compared with that of control group (P<0.01). Conclusions: Short-term use of atorvastatin can decrease serum levels of CRP and BNP in Patients of HF with DCM,and improve cardiac function. The mechanism of action may be related to anti-inflammatory effect. It may be useful to short-term use of statin therapy.

       

      • HTML全文
      • 参考文献(0)
      • 相关文章
      • 施引文献
    • 资源附件(0)

    /

    返回文章
    返回